Peptide Frag 176-19

Fragment 176-191 or Frag 176-191 or HGH Frag 176-191 is the modified part of the amino acid sequence of human growth hormone. Scientists found out that it is possible to isolate the attributes of fat loss associated with HGH by truncating the HGH peptide at its C terminal region. They also found out that this fragment from HGH, which includes the peptide bonds 176-191, is 12.5 times better in regulating fat loss than the regular HGH. Studies on animals have shown that Frag 176-191 has the ability to improve muscle mass and lipid profile as it has the traits of both peptides and hormones. More information can be found at if interested in additional research.

History of Frag 176-191

It was in the 1970s that the studies on Frag 176-191 were initiated. Scientists worked on similar protein groups in order to determine their physical configurations as well as overall functions. They found out the relationship between protein functions, their physical configurations and informational sequences. By 1984, they learnt that Frag 176-191 is responsible not only for protein binding but also conformational alterations in certain areas due to the presence of protease and proline in high amounts.

Mechanism of Action

Study on animal subjects has revealed that Frag 171-196 imitates the way in which HGH controls fat metabolism. Additionally, it carries out this task without adversely affecting either blood sugar levels or cellular proliferation. Therefore, the benefits offered by this peptide include the following: efficient breaking down of adipose tissues, increased rate of energy expulsion and fat oxidation, promotion of muscle mass.

In addition, Frag 176-191 maintains the configuration of various fatty acids and lipids throughout the body. Further, clinical research studies have also demonstrated the peptide’s potential to slow down the process of aging and improve mental health among animal test subjects. Scientists have observed that HGH Frag 176-191 helps to stop the basal lesions seen during the initial stage of development of Parkinson’s disease and counteract the toxicity caused by protein malfunctions at the onset of Alzheimer’s disease.


As of now the functionality of Frag 176-191 has been studied only on animal subjects. Therefore, the information provided in this article is only for developing an understanding of the subject matter.